ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
07/27/2022
Back to search
Official data from USPTO
TAVANTA THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
TAVANTA THERAPEUTICS
ST13
US500000088916837Class
42
Filing
88916837
Registration
6521716
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
29
Latest update
07/27/2022
Trademark type
Word
Nice classes
42
Filing date
05/14/2020
Registration date
10/12/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/12/2021
Last transaction
10/12/2021
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
09/01/2020
First use in commerce
09/01/2020
Drawing code
4
Owner type
03
Owner location
RADNOR, PA
Examiner
CUELLO, GIDETTE
Law office
N70
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
TAVANTA THERAPEUTICS, INC.
Druggability Technologies Holdings, Ltd
Representatives
Thomas G. Peterson MAYNARD COOPER GALE
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Scientificmedical and pharmaceutical research and developmentdevelopment of new pharmaceutical formulationsdevelopment of pharmaceutical formulations for efficient drug releasedevelopment of clinical uses and treatments for new chemical entities and known pharmaceutical compounds; research and development of new pharmaceutical formulations; research and development of pharmaceutical formulations for efficient drug release; research and development of pharmaceuticalspharmaceuticals for treating cancermultiple sclerosiscystic fibrosistuberous sclerosis complexother disease states; research and development of new chemical entities and known pharmaceutical compounds; research and development of medicinesfor the treatment of cancermultiple sclerosiscystic fibrosistuberous sclerosis complexother disease states; scientific investigations for medical purposes; research and development of medicinesnew chemical entities and known pharmaceutical compounds
Publications
History of USPTO decisions and trademark events.
29 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
10/12/2021
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
09/09/2021
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
09/08/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/03/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/03/2021
ALIE
ASSIGNED TO LIE
08/03/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/30/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
07/21/2021
GNRT
NON-FINAL ACTION E-MAILED
07/21/2021
CNRT
SU - NON-FINAL ACTION - WRITTEN
07/21/2021
SUPC
STATEMENT OF USE PROCESSING COMPLETE
06/22/2021
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
06/17/2021
IUAF
USE AMENDMENT FILED
06/08/2021
EISU
TEAS STATEMENT OF USE RECEIVED
06/08/2021
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
12/08/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/13/2020
PUBO
PUBLISHED FOR OPPOSITION
10/13/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/23/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/10/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/09/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/08/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/08/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/18/2020
GNRT
NON-FINAL ACTION E-MAILED
08/18/2020
CNRT
NON-FINAL ACTION WRITTEN
08/18/2020
DOCK
ASSIGNED TO EXAMINER
08/12/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/28/2020
NWAP
NEW APPLICATION ENTERED
05/18/2020
Continuous trademark protection
Get notified about every new filing that threatens TAVANTA THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.